Cargando…
PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer
Colon cancer is the third most common cancer in humans which has a high mortality rate, and 5-Fluorouracil (5-FU) is one of the most widely used drugs in colon cancer therapy. However, acquired chemoresistance is becoming the major challenges for patients, and the molecular mechanism underlying the...
Autores principales: | Wang, Huanan, Zhang, Lingling, Yang, Xu, Jin, Yipeng, Pei, Shimin, Zhang, Di, Zhang, Hong, Zhou, Bin, Zhang, Yingjie, Lin, Degui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546474/ https://www.ncbi.nlm.nih.gov/pubmed/25965911 |
Ejemplares similares
-
NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017) -
Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
por: Tian, Li, et al.
Publicado: (2018) -
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016) -
The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
por: Yu, Cheng-Chan, et al.
Publicado: (2020) -
The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma
por: Wang, Yao, et al.
Publicado: (2022)